DBV Technologies company info

What does DBV Technologies do?
DBV Technologies (EPA:DBV), (NASDAQ:DBVT) is a biopharmaceutical company focused on developing and commercializing treatments for food allergies, particularly peanut allergies in children, through its innovative Viaskin technology. This epicutaneous immunotherapy (EPIT) platform leverages a patch-based approach aiming to provide a non-invasive treatment option for patients. DBV Technologies is committed to improving the lives of those suffering from food allergies by advancing research and striving towards the commercial availability of their treatments. Operating with a strong commitment to safety, efficacy, and patient accessibility, their primary objective is to bring transformative therapies to the market, addressing a significant unmet need within the allergy therapeutic space.
DBV Technologies company media
Company Snapshot

Is DBV Technologies a public or private company?

key
Ownership
Public

How many people does DBV Technologies employ?

people
Employees
105

What sector is DBV Technologies in?

pie chart
Sector
Health Care

Where is the head office for DBV Technologies?

location pin
Head Office
Bagneux, France

What year was DBV Technologies founded?

founded flag
Year Founded
2002
What does DBV Technologies specialise in?
/Immunotherapy solutions /Patch Technology /Food Allergies /Drug Development /Pediatric Medicine /Diagnostic Tools

What are the products and/or services of DBV Technologies?

Overview of DBV Technologies offerings
Viaskin Patch, a novel immunotherapy platform aimed at treating food allergies through epicutaneous delivery.
Viaskin Peanut, designed for children aged 4-11 with peanut allergies, seeking FDA approval.
Product pipeline includes Viaskin Milk for milk allergy treatment and Viaskin Egg for egg allergy, both in early development stages.
Collaborations with academic and industry partners to explore Viaskin's platform for other allergies.
Research and development in novel diagnostic tools for food allergies.
Expanding applications of the Viaskin platform to address other immune-related disorders beyond allergies.

Who is in the executive team of DBV Technologies?

DBV Technologies leadership team
  • Mr. Daniel  Tassé
    Mr. Daniel Tassé
    CEO & Director
  • Dr. Pharis  Mohideen
    Dr. Pharis Mohideen
    Chief Medical Officer
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.
    Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.
    CFO & Principal Accounting Officer
  • Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.
    Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.
    Chief Operations Officer
  • Ms. Michele F. Robertson
    Ms. Michele F. Robertson
    Chief Legal Officer
  • Ms. Caroline  Daniere
    Ms. Caroline Daniere
    Chief Human Resources Officer & Chief of Staff
  • Dr. Wence  Agbotounou
    Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Senior VP
  • Mr. Edward P. Jordan M.B.A.
    Mr. Edward P. Jordan M.B.A.
    Senior Vice President of Commercial Operations North America